The estimated Net Worth of Jin Long Chen is at least 12.3 百万$ dollars as of 17 January 2023. Jin Chen owns over 85,082 units of Ngm Biopharmaceuticals Inc stock worth over 1,530,722$ and over the last 5 years he sold NGM stock worth over 8,885,300$. In addition, he makes 1,917,600$ as Founder、 Chief Scientific Officer、 Director at Ngm Biopharmaceuticals Inc.
Jin has made over 21 trades of the Ngm Biopharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 85,082 units of NGM stock worth 122,518$ on 17 January 2023.
The largest trade he's ever made was exercising 150,000 units of Ngm Biopharmaceuticals Inc stock on 4 January 2021 worth over 90,000$. On average, Jin trades about 40,560 units every 47 days since 2019. As of 17 January 2023 he still owns at least 993,975 units of Ngm Biopharmaceuticals Inc stock.
You can see the complete history of Jin Chen stock trades at the bottom of the page.
Dr. Jin-Long Chen Ph.D. serves as Founder, Chief Scientific Officer, Director of the Company. Dr. Chen has served as a member of our Board of Directors and as our Chief Scientific Officer since January 2008. From 2004 to 2008, Dr. Chen held various positions at Amgen, most recently as its Vice President, Metabolic Research. Prior to joining Amgen, Dr. Chen was Vice President, Biology at Tularik. He has served as a director of Tenaya Therapeutics, Inc. since 2016. Dr. Chen received a B.S. from Fu-Jen Catholic University, an M.S. from National Taiwan University and a Ph.D. from the University of California, Berkeley. Chen’s extensive experience with NGM, which is a consequence of his long tenure as Chief Scientific Officer, brings necessary historic knowledge and continuity to our Board of Directors. In addition, we believe that his experiences prior to joining us provided him with operational and industry expertise that are important to our Board of Directors.
As the Founder、 Chief Scientific Officer、 Director of Ngm Biopharmaceuticals Inc, the total compensation of Jin Chen at Ngm Biopharmaceuticals Inc is 1,917,600$. There are 1 executives at Ngm Biopharmaceuticals Inc getting paid more, with David Woodhouse having the highest compensation of 2,092,150$.
Jin Chen is 57, he's been the Founder、 Chief Scientific Officer、 Director of Ngm Biopharmaceuticals Inc since . There are 8 older and 9 younger executives at Ngm Biopharmaceuticals Inc. The oldest executive at Ngm Biopharmaceuticals Inc is David Goeddel, 68, who is the Lead independent director.
Jin's mailing address filed with the SEC is C/O NGM BIOPHARMACEUTICALS, INC., 333 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 6 years, insiders at Ngm Biopharmaceuticals Inc have traded over 9,159,599$ worth of Ngm Biopharmaceuticals Inc stock and bought 18,889,291 units worth 177,396,366$ . The most active insiders traders include Peter Svennilson、David V Goeddel、Group L P Svennilson Peter .... On average, Ngm Biopharmaceuticals Inc executives and independent directors trade stock every 9 days with the average trade being worth of 171,092$. The most recent stock trade was executed by Group L Ptcg Opportunity Ii... on 15 November 2023, trading 22,631 units of NGM stock currently worth 15,615$.
ngm bio is a research-driven, clinical stage biopharmaceutical company with a drug discovery platform designed to generate a pipeline of first-in-class biologic drug candidates. our initial r&d focus has been on cardio-metabolic and liver disease, but we believe that our research expertise – comprehensive and grounded in fundamental, interrelated mechanisms of human biology – is capable of driving the development of new therapies for a wide range of disease areas such as cancer. ngm bio’s comprehensive approach to drug discovery focuses on elucidating the biology of hormones, cell receptors and associated ligands. as we investigate these novel biological mechanisms, we assemble a deep understanding of the relationship between the structure and function of proteins of interest. coupled with our experience in protein and antibody engineering, our approach enables the efficient and targeted generation of potential first-in-class therapeutics with optimized pharmacologic profiles. work
Ngm Biopharmaceuticals Inc executives and other stock owners filed with the SEC include: